CorrectSequence Therapeutics’ CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy

SHANGHAI, Nov. 6, 2025 /PRNewswire/ — On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital. 

The patient, diagnosed with chylomicronemia, had a long history of fasting triglyceride (TG) levels exceeding 12.5 mmol/L and recurrent acute pancreatitis. In the dose-escalation IIT for CS-121, his fasting TG level dropped significantly within three days after a single low-dose administration, with no adverse events.

This is the world’s first successful clinical treatment of hyperlipidemia with the gene-editing therapy targeting APOC3.

Picture: The world’s first patient of the gene-editing therapy targeting APOC3 (Correctseq’s CS-121) for hyperlipidemia (the 6th from the right) has successfully completed dosing and been discharged.

Chylomicronemia is a metabolic disorder characterized by abnormally elevated chylomicrons in the blood, associated with lipid metabolism dysfunction, leading to extremely high fasting TG levels and potentially life-threatening complications such as acute pancreatitis. It is the most severe subtype of severe hypertriglyceridemia (sHTG), including Familial Chylomicronemia Syndrome (FCS) and Multifactorial Chylomicronemia Syndrome (MCS). FCS is a rare autosomal recessive disorder caused by biallelic mutations in the Lipoprotein Lipase (LPL) gene or other key regulatory genes, with fasting TG ≥10 mmol/L (885 mg/dL) and a global prevalence of 1 in 100,000–1,000,000. MCS results from a complex interaction of genetic, lifestyle, or metabolic disorders with a prevalence as high as 1 in 600 worldwide.

Current treatments for chylomicronemia primarily aim to control fasting TG levels below the acute pancreatitis risk threshold (<5.7 mmol/L or 500 mg/dL), but available triglyceride-lowering medications are often insufficient, and very-low-fat diets are hard to maintain in a long-term manner.

Scientific studies have shown that the APOC3 protein, produced in the liver, plays a central role in TG regulation. Large-scale population analyses have shown that individuals carrying natural APOC3 loss-of-function mutations have significantly lower TG levels without adverse effects. With advances in gene-editing technologies, it is now possible to therapeutically modulate APOC3 expression at the genetic level to lower TG levels — offering a potential curative strategy for chylomicronemia and hypertriglyceridemia.

CS-121, Correctseq’s first in vivo gene-editing therapy for chylomicronemia and hypertriglyceridemia, is based on the transformer Base Editor (tBE) — a highly precise base-editing system independently developed by Correctseq’s scientific co-founders. Administered via intravenous injection, tBE is delivered via lipid nanoparticles (LNPs) to the liver and precisely edits the target APOC3 gene. It mimics beneficial natural APOC3 loss-of-function variants to downregulate APOC3 expression and effectively lower plasma TG levels. By addressing the disease at the genetic level, this therapy aims to achieve “one-time treatment, lifelong efficacy.”

CS-121 utilizing the next-generation tBE technology, which enables precise single-base correction without DNA double-strand breaks, offering superior safety over the gene-editing therapies based on CRISPR. tBE avoids potential safety risks such as p53 activation, chromosomal damage, off-target effects, and liver toxicity caused by DNA double-strand breaks. Preclinical animal studies showed excellent safety and long-term efficacy, with no off-target editing detected in various organs including liver, lungs, muscle, spleen, ovaries, heart, and kidneys.

The first patient, a 63-year-old male, received a single low-dose intravenous administration on October 18, 2025. His fasting TG levels dropped significantly within three days after the treatment, and he was discharged three days post-treatment with no treatment-related adverse events to date.

The principal investigators of the CS-121 IIT are Professor Huan Zhou and Doctor Zhili Wu from the First Affiliated Hospital of Anhui Medical University.

Correctseq, an innovative biotechnology company at the IND clinical stage, previously developed CS-101, an ex vivo gene-editing therapy that has successfully treated dozens of patients with β-thalassemia and sickle cell disease. The company is advancing the first in vivo gene-editing therapy CS-121 toward IND clinical trials and commercialization, aiming to offer “one-time treatment, lifelong efficacy” treatment for patients with chylomicronemia, hypertriglyceridemia, and other metabolic disorders.

Acknowledgments: The First Affiliated Hospital of Anhui Medical University, ShanghaiTech University, Shanghai Clinical Research and Trial Center.

About CorrectSequence Therapeutics
CorrectSequence Therapeutics (Correctseq), incubated at ShanghaiTech University, is dedicated to leveraging innovative gene-editing technologies to transform the lives of people with severe diseases. The company has developed multiple state-of-the-art base-editing systems that offer exceptional precision, minimize off-target effects, and enhance in vivo editing efficiency. Its robust pipeline spans genetic disorders, metabolic diseases, and cardiovascular conditions, with several programs already advancing toward clinical development.

For more information, visit www.correctsequence.com.

Media Contact:
Business Cooperate: BD@correctsequence.com
Clinical Trial Recruitment: CT@correctsequence.com

Integration Reinforces FreshCloud as the Industry’s Most Connected Digital Quality Ecosystem

PHILADELPHIA, Nov. 6, 2025 /PRNewswire/ — AgroFresh Solutions, Inc., a global leader in post-harvest freshness solutions, continues to expand its FreshCloud™ digital ecosystem through two strategic global partnerships. Collaborations with Aerobotics, a leader in orchard and packhouse analytics, and Neolithics™, a pioneer in AI-powered quality inspection, position FreshCloud to be the most comprehensive digital produce quality and supply chain management platform in the fresh produce industry.

By aggregating real-time data from multiple sources, FreshCloud offers more options at each step in the fresh produce supply chain for digitally integrated, quality measurements. Building on its existing partnerships with sensor innovators Rubens Technologies, Strella, and Escavox, AgroFresh continues to expand its connected sensor platform for post-harvest management. This growing ecosystem empowers growers, packers and retailers to make faster, data-backed decisions to reduce waste, improve quality, and drive profit potential.

“AgroFresh is committed to building the most holistic and connected digital platform in fresh produce,” said Bradford Warner, AgroFresh Head of Digital Solutions. “By integrating partners like Aerobotics and Neolithics, FreshCloud now connects orchard-to-packhouse intelligence like never before.”

Accurate Yield Data with TrueFruit^® by Aerobotics

AgroFresh’s partnership with Aerobotics integrates multiple TrueFruit^® modules into FreshCloud™, delivering AI-powered orchard and packhouse intelligence. Using computer vision and AI analysis of smartphone imagery, Aerobotics enables growers to:

• Measure fruit size, color, and quality accurately and objectively.
• Improve harvest planning with accurate size forecasting, blemish detection, and color grading models.
• Monitor quality with standardized measurements, from the orchard to the packhouse.
• View yield data in one place for informed decisions that boost packouts by an average of 1-5%, providing more than 10 times return on investment for commercial customers.

“Aerobotics has always focused on empowering growers and packers with highly accurate yield,” said James Paterson, CEO of Aerobotics. “We are excited to partner with AgroFresh, as a key leader in our industry, to offer TrueFruit^® to more customers and combine the power of our technology with FreshCloud™. Together, these solutions seamlessly extend insights from the orchard into the post-harvest stage, providing continuity of data and enhancing decisions across the value chain.”

Next-Generation Quality Control with Neolithics

With Neolithics integrated into AgroFresh’s FreshCloud, packers have access to a technology that delivers quality assurance to match the speed and scale of the modern packhouse, turning inspection into a source of confidence versus risk. Neolithics’ AI-powered imaging:

• Provides high-throughput inspection, from one kilogram per minute for berries to over six tons per hour for avocados, scanning every piece for internal and external quality.
• Measures key parameters such as brix, acidity, and dry matter, while detecting hidden internal and surface defects.
• Completes this process without destroying a single piece of fruit, all above 90% accuracy.

“We want to enable customers to protect their produce through high-volume, non-destructive quality inspections by reducing waste and creating greater transparency from field to shelf,” said Kate Murray, CEO of Neolithics. “We’re excited to integrate with AgroFresh and their FreshCloud ecosystem to realize our shared vision for a more sustainable, transparent food chain.”

Discover how AgroFresh and its partners are advancing digital quality innovation by connecting with us through the contact us form.

About AgroFresh
AgroFresh is a global leader in post-harvest quality and freshness solutions, dedicated to enhancing the quality and extending the shelf-life of fresh produce while reducing food loss and waste. With over 40 years of innovation, AgroFresh addresses supply chain challenges from all angles, offering a full suite of integrated storage, packing line, and digital solutions. AgroFresh empowers growers, packers, and retailers to deliver fresh, quality, and sustainable produce from harvest to home. Learn more at www.agrofresh.com.

About Aerobotics
Powered by Aerobotics’ industry-leading computer vision, TrueFruit^® is a comprehensive suite of AI tools to help fruit companies better measure and estimate their yield. TrueFruit^® uses smartphone imagery and machine learning to accurately size and grade fruit, providing precise and objective measurements to aid forecasting and estimation. TrueFruit^® is used by leading fruit companies worldwide, helping improve packouts and enhance returns. Learn more at aerobotics.com.

About Neolithics
Neolithics™ is an AI agri-tech company leveraging advanced food science and optical sensing technology to revolutionize fresh produce inspection. Named for the Neolithic period, the dawn of agriculture, Neolithics brings that same spirit of transformation to modern food systems. Its flagship technology, in use by Neolithics Light devices, uses AI and optical sensors to deliver fast, accurate, and non-destructive quality analysis in real time, helping reduce food waste, ensure food safety, and improve efficiency across production environments. Learn more at www.neolithics.ai.

MELBOURNE, Australia, Nov. 6, 2025 /PRNewswire/ — A drop in gold prices on Oct. 23 has shifted market sentiment, with The Australian reporting the decline may signal opportunity for the Australian dollar. As volatility renews retail interest, CFD platform Mitrade has reaffirmed its commitment to trading education. It was recently named “Best Educational Resources” at the Global Forex Awards 2025 – Retail, a program that received more than 200,000 public votes across 400 nominated firms. 

Australia kicked off 2025 strong, ranking fourth globally in active CFD trader numbers, with about 81,000 retail users, according to Finance Magnates’ Q1 2025 Intelligence Report. Despite rising participation, financial literacy remains a major challenge. The University of New South Wales reports that about 45% of the population is considered financially illiterate. This knowledge gap is consequential as ASIC has renewed its call for Australians to make better informed decisions following a rise in retail investor complaints.  

“Market volatility draws in more retail traders across the industry, but many begin their journey with surface-level understanding of risks,” said Elven Jong, CEO of Mitrade Global. “This literacy gap shows up in real time — in the way people respond to price swings, use leverage, or misjudge market signals.” 

He added, “ASIC has made consumer protection central to the industry, but protection also starts from trader knowledge. We embed educational resources and real-time insights into our platform because we see education as our responsibility to support Australia’s broader financial literacy efforts.” 

This recognition is one of 16 Mitrade awards received globally in 2025, including four in Australia. Founded in Melbourne, the platform combines local focus with global standards, reflecting its vision to equip traders with the tools and knowledge to navigate markets responsibly. 

About Mitrade 
Mitrade is an award-winning CFD trading platform founded in Melbourne, trusted by 6M+ traders worldwide. It operates under top-tier financial regulators—Australia’s ASIC (AFSL398528), Cyprus’ CySEC (CIF438/23), the Cayman Islands’ CIMA (SIB1612446), South Africa’s FSCA (54842), and Mauritius’s FSC (GB20025791)—delivering a secure, seamless, and intuitive trading experience. 

The platform provides 800+ CFDs on indices, forex, commodities, ETFs, and shares. Mitrade redefines trading with microsecond execution, razor-thin spreads, robust risk management, and multi-device compatibility. 

Trading involves risk. This article is for informational purposes only and does not constitute financial advice, an offer, or a solicitation. 

Visit https://www.mitrade.com for more information.

STRASSEN, Luxembourg, Nov. 6, 2025 /PRNewswire/ — FAGE International S.A. (the “Company” or “FAGE”) a leading international Greek yogurt company, today announced a new global partnership with Ferrari. Beginning in 2026, FAGE will join Ferrari Hypercar in the FIA World Endurance Championship (WEC) – the world’s premier international sports car championship that includes the legendary 24 Hours of Le Mans.

FAGE and Ferrari executives join Ferrari – AF Corse team to celebrate partnership launch. From left to right: Enrico Galliera, Athanassios Filippou, James Calado, Antonio Giovinazzi, Alessandro Pier Guidi, Nicklas Nielsen, Miguel Molina, Antonio Fuoco, Kyros Filippou, Antonello Coletta

This announcement follows FAGE’s 2025 regional sponsorship of the Ferrari Challenge Trofeo Pirelli, one of the world’s most renowned single-marque racing series, and represents a significant expansion of the relationship between two brands united by passion, pursuit of performance and craftsmanship.

Driven by such values, FAGE has chosen to join Ferrari’s successful Hypercar program in a collaboration that marks the beginning of a journey combining the pursuit of performance and flavor. In this perspective, FAGE-led culinary experiences will aim to celebrate the spirit of Ferrari beyond the racetrack.

Through this partnership, FAGE becomes a voice for the importance of nutrition — not only as a foundation for everyday health, but as a driving force behind elite performance. As drivers must carefully train balance, strength, and endurance, FAGE embodies the same principles. This collaboration celebrates how mindful nutrition can empower everyone to pursue excellence — on and beyond the racetrack.

Athanassios Filippou, FAGE’s CEO commented: “We’re proud of our growing relationship with Ferrari Hypercar, and this announcement shows our commitment to excellence with a like-minded, iconic brand. Additionally, this partnership will allow us to show customers how nutrition has a strong impact on overall performance.”

We are delighted to partner with FAGE,” said Antonello Coletta, Ferrari Global Head of Endurance and Corse Clienti. “We share common values such as passion, excellence, and the pursuit of continuous improvement. FAGE’s commitment to quality and authenticity aligns perfectly with the spirit of Ferrari’s Hypercar programme. They join a select group of partners who contribute to our ongoing drive for innovation and success.

About FAGE

FAGE is a leading dairy company passionate about sharing the finest dairy products with food lovers around the globe. Founded in Greece in 1926, FAGE has grown from its Greek roots into an international brand, offering exceptional dairy products in over 30 countries. Best known for its signature Greek strained yogurt, FAGE continues to inspire healthy lifestyles and deliver deliciously crafted products.

Filigran evolves OpenBAS into OpenAEV, expanding from control validation to full threat exposure management. The new OpenAEV Enterprise Edition introduces advanced automation and AI to help security teams continuously validate and reduce cyber risk.

PARIS, Nov. 6, 2025 /PRNewswire/ — Filigran, the European cybertech company specializing in open-source cybersecurity solutions, announces a major step in its leadership in exposure management and support for Continuous Threat Exposure Management (CTEM). Its breach and attack simulation (BAS) platform has been rebranded as OpenAEV (Adversarial Exposure Validation), alongside the launch of a new Enterprise Edition (EE) for advanced security teams.

This evolution marks a shift from simulation to a full AEV paradigm—an approach that unifies proactive exposure assessment and risk reduction. OpenAEV delivers a broader, adaptive, and threat-informed defense strategy, enabling organizations to validate their security posture continuously, across both technical and human dimensions.

“With OpenAEV, we’re enabling teams to continuously and proactively assess their defenses. It’s not just about simulating attacks, but understanding what truly matters to reduce risk. Our goal is to help CISOs enhance their AEV capabilities, both technically and humanly” explains Samuel Hassine, CEO of Filigran.

OpenAEV: Priroritize, Test and Fix

OpenAEV is the first open-source, threat intelligence-driven AEV platform. It gives organizations a proactive framework to anticipate and neutralize cyber threats before they strike.

OpenAEV helps organizations:

• Prioritize defenses based on relevant threats and critical vulnerabilities
• Validate security controls like EDRs and firewalls through realistic attack emulation
• Test human readiness via tabletop exercises
• Accelerate remediation with actionable control guidance

Launch of the Enterprise Edition: AI at the Core of Validation

The Community Edition (CE) remains free and open-source, while the new Enterprise Edition (EE) brings advanced automation for large organizations.

Key features include:

• AI-assisted scenario generation for faster processing of threat intelligence and CERT reports
• Multi-option remediation recommendations for risk-based prioritization and sequencing
• Validation through existing EDR agents for seamless execution and without requiring additional overheads on already resource-constrainted endpoints
• SaaS environment hosted by Filigran and dedicated customer support.

With OpenAEV, Filigran reaffirms its mission: to transform threat and exposure data into validated, actionable security outcomes, through the industry’s first open-source, threat-informed AEV platform.

About Filigran

Founded in 2022, Filigran designs open-source solutions that make threat intelligence actionable for cybersecurity teams. Its platforms are trusted by over 6,000 organizations worldwide.

Learn more: Website – Blog – LinkedIn – X/Twitter

Contact: contact@mcb.mu